摘要
目的探索丙型肝炎病毒(HCV)感染对胃肠道肿瘤患者接受术后辅助化疗的影响。方法回顾性选取合并HCV感染手术后需要立即接受术后辅助化疗的胃肠道肿瘤患者为研究组(29例),选取HCV阴性并接受术后辅助化疗的胃肠道肿瘤患者为对照组(59例)。比较两组的一般资料和临床特征,分析HCV感染对胃肠道肿瘤患者接受术后辅助化疗的影响。结果研究组的基线谷丙转氨酶(ALT)水平高于对照组,化疗后的ALT水平升高更为显著(P<0.05)。研究组的严重不良事件(SAEs)及不良事件(AEs)的总发生率均高于对照组(P<0.05)。研究组在化疗期间出现化疗延期及化疗药物减量的概率明显高于对照组,差异具有统计学意义(P<0.05)。结论HCV阳性的胃肠道肿瘤患者在接受术后辅助化疗时更容易出现不良反应;HCV阳性阻碍化疗的顺利完成,应该予以密切监测。
Objective To investigate the effect of hepatitis C virus(HCV)infection on postoperative adjuvant chemotherapy in patients with gastrointestinal cancer.Methods The patients with gastrointestinal cancer and HCV infection who needed immediate postoperative adjuvant chemotherapy were retrospectively selected as study group(29 cases),and the patients with gastrointestinal cancer who were HCV negative received postoperative adjuvant chemotherapy were selected as control group(59 cases).The general information and clinical characteristics of the two groups were compared,and the effect of HCV infection on postoperative adjuvant chemotherapy in patients with gastrointestinal cancer was analyzed.Results The baseline alanine transaminase(ALT)level of the study group was higher than that of the control group,and the increase of ALT level after chemotherapy was more significant(P<0.05).The total incidences of severe adverse events(SAEs)and adverse events(AEs)in the study group were higher than those in the control group(P<0.05).The probability of chemotherapy delay and chemotherapy drug reduction in the study group were significantly higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The patients with HCV-positive gastrointestinal cancer are more likely to have adverse reactions during postoperative adjuvant chemotherapy;HCV pasitive hinders the successful completion of chemotherapy and should be closely monitored.
作者
卫鑫
宋东峰
WEI Xin;SONG Dongfeng(Oncology Department,Shaanxi Provincial People's Hospital,Xi'an 710068,China;Psychology Department,Shaanxi Provincial People's Hospital,Xi'an 710068,China)
出处
《临床医学研究与实践》
2024年第8期47-51,共5页
Clinical Research and Practice
基金
陕西省人民医院科技人才支持计划-菁英人才项目(No.2022JY-43)
希思科-和记黄埔医药肿瘤研究基金(No.Y-HH202101-0234)。
